Clinical Trial Detail

NCT ID NCT02864251
Title A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in NSCLC Patients With EGFR Mutation Who Failed 1L or 2L EGFR TKI Therapy (CheckMate722)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Bristol-Myers Squibb

lung non-small cell carcinoma


Carboplatin + Nivolumab + Pemetrexed Disodium

Cisplatin + Pemetrexed Disodium

Cisplatin + Nivolumab + Pemetrexed Disodium

Ipilimumab + Nivolumab

Carboplatin + Pemetrexed Disodium

Age Groups: senior adult

Additional content available in CKB BOOST